Granted Patent
B2
US 12,453,738 · App. 17/438,186 · Granted Oct 28, 2025
Treatment of oncogene-driven cancers
Inventors:
Joanne B.L. Tan (San Francisco, CA); Akshata R. Udyavar (Foster City, CA); Stephen W. Young (Palomar Park, CA)
Assignee:
ARCUS BIOSCIENCES, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods of treating a subject identified as having an oncogene driven cancer comprising administering to said subject an agent targeting the extracellular production of adenosine and/or an agent antagonizing the activation by adenosine of one of its receptors.
Claims (10)
1. A method of treating a subject identified as having an oncogene driven cancer comprising administering to said subject a therapeutically effective amount of Compound A
or a pharmaceutically acceptable salt thereof;
and wherein the an oncogene driven cancer has a mutation in KRAS.
2. The method of claim 1 , further comprising administering one or more additional therapeutic agents.
3. The method of claim 1 , further comprising administering an immune checkpoint inhibitor.
4. The method of claim 3 , wherein the immune checkpoint inhibitor blocks the activity of at least one of PD1, PDL1, BTLA, LAG3, a B7 family member, TIM3, TIGIT or CTLA4.
5. The method of claim 1 , further comprising administering a chemotherapeutic agent.
6. The method of claim 5 , wherein the chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent or taxoid.
7. The method of claim 1 , wherein the oncogene driven cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, or testicular seminoma.
8. The method of claim 1 , wherein the oncogene driven cancer is a cancer of the thyroid, adrenal gland, mesothelial lining, bile duct, pancreas, brain, kidney, esophagus, rectum, colon, stomach, head, neck, skin, testis, ovary, lung, endometrium, eye, prostate, breast, or liver; or is glioblastoma, mesothelioma or sarcoma.
Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR'S NAME STEVEW. YOUNG PREVIOUSLY RECORDED ON REEL 058442 FRAME 0933. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Jun 3, 2022
From: TAN, JOANNE B. L.; UDYAVAR, AKSHATA R.; YOUNG, STEPHEN W.
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 061280/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 21, 2021
From: TAN, JOANNE B.L.; UDYAVAR, AKSHATA R.; YOUNG, STEVE W.
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 058442/0933 →
Continuity (2)
Provisional Application
62817425
· Mar 12, 2019
References Cited (104)
US 20160129108A1
· Sachsenmeier et al.
· 2016
[cited by applicant]
US 20190022096A1
· Willingham et al.
· 2019
[cited by applicant]
US 20210395391A1
· Zhu et al.
· 2021
[cited by applicant]
WO WO03050241A2
· 2003
[cited by applicant]
WO WO2004079013A1
· 2004
[cited by applicant]
WO 2012031320
· 2012
[cited by applicant]
WO WO2015031320A1
· 2015
[cited by applicant]
WO 2016075176
· 2016
[cited by applicant]
WO WO2016075099A1
· 2016
[cited by applicant]
WO 2017040930
· 2017
[cited by applicant]
WO WO2017120508A1
· 2017
[cited by applicant]
WO WO2017152085A1
· 2017
[cited by applicant]
WO 2018067424
· 2018
[cited by applicant]
WO WO2018067424A1
· 2018
[cited by applicant]
WO WO2018094148A1
· 2018
[cited by applicant]
WO WO2018136700A1
· 2018
[cited by applicant]
WO WO2018137598A1
· 2018
[cited by applicant]
WO 2018187512
· 2018
[cited by applicant]
WO WO2018187484A1
· 2018
[cited by applicant]
WO WO2018187508A1
· 2018
[cited by applicant]
WO WO2018204661A1
· 2018
[cited by applicant]
WO WO2018213377A1
· 2018
[cited by applicant]
WO WO2018237173A1
· 2018
[cited by applicant]
WO 2019007140
· 2019
[cited by applicant]
WO WO2019090347A1
· 2019
[cited by applicant]
WO WO2019161054A1
· 2019
[cited by applicant]
WO 2019168744
· 2019
[cited by applicant]
WO WO2019173682A1
· 2019
[cited by applicant]
WO 2019200256
· 2019
[cited by applicant]
WO WO2019206872A1
· 2019
[cited by applicant]
WO WO2020018680A1
· 2020
[cited by applicant]
WO WO2020023846A1
· 2020
[cited by applicant]
WO WO2020046813A1
· 2020
[cited by applicant]
WO WO2020123772A1
· 2020
[cited by applicant]
WO WO2020205527A1
· 2020
[cited by applicant]
WO WO2021138498A1
· 2021
[cited by applicant]
Morrison et al. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4(6): 418-428, 2018, Published online Apr. 28, 2018. (Year: 2018).
[cited by examiner]
U.S. Appl. No. 17/193,473, filed Mar. 5, 2021, Lawson et al.
[cited by applicant]
U.S. Appl. No. 17/346,918, filed Jun. 14, 2021, Beatty et al.
[cited by applicant]
U.S. Appl. No. 17/507,921, filed Oct. 22, 2021, Beatty et al.
[cited by applicant]
International Search Report and Written Opinion dated Oct. 14, 2021 in PCT/US2020/025242, 11 pages.
[cited by applicant]
International Search Report and Written Opinion dated Sep. 23, 2021 in PCT/US2020/022028, 8 pages.
[cited by applicant]
Mittal et al., “Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor,” Cancer Research, Jul. 1, 2014, 74(14):3652-3658.
[cited by applicant]
Morello et al., “Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab,” J. Transl. Med., Dec. 4, 2017, 15:244, 1-9.
[cited by applicant]
Stagg et al., “Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis,” PNAS, Jan. 26, 2010, 107(4):1547-1552.
[cited by applicant]
“33rd Annual Meeting & Pre-Conference 2-9,16, Programs of the Society for Immunotherapy of Cancer (SITC 2018)”, Journal for Immunotherapy of Cancer, Biomed Central Ltd, London, UK, vol. 6, No. 1, Nov. 6, 2018 (Nov. 6, 2…
[cited by applicant]
“Research 1-15, Poster Presentation Design 2015”, Mar. 29, 2019 (Mar. 29, 2019), pp. 1-1, XP055972348, Retrieved from the Internet: URL:https://arcusbio.com/wpcontent/uploads/2020/09/AACR-2019-Biomarkers-poster.pdf> * t…
[cited by applicant]
Dipti Vijayan et al: “Targeting immunosuppressive adenosine in cancer”, Nature Reviews Cancer, vol. 17, No. 12, Oct. 23, 2017 (Oct. 23, 2017), pp. 709-724, XP055557876, London ISSN: 1474-175X, DOI: 10.1038/nrc.2017.86.
[cited by applicant]
Direnzo Daniel et al: “Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928”, Cancer Research, vol. 79, No. 13_Supplement, Jul. 1, 2019 (Jul. 1, 2019), pp. 3168-3168, XP055972…
[cited by applicant]
European Patent Office Search Report on EP application 20782135.6 dated Nov. 22, 2022 (16 pages).
[cited by applicant]
Extended European Search Report issued in connection with EP Appl. Ser. No. 20770898.3 dated Oct. 17, 2022.
[cited by applicant]
Le et al: “CD73 inhibition enhances the effect of anti-PD-1 therapy on KRAS-mutated pancreatic cancer model”, Cancer Immunology Research Jul. 2014; AACR Special Conference on Tumor Immunology and Immunotherapy, Nov. 17,…
[cited by applicant]
Pedraza-Farina Laura G: “Mechanisms of Oncogenic Cooperation in Cancer Initiation and Metastasis”, Yale Journal of Biology and Medicine, Jan. 1, 2006 (Jan. 1, 2006), pp. 95-103, XP055967921, Retrieved from the Internet:…
[cited by applicant]
Roberto Leone et al: “Targeting adenosine 1,3-6, for cancer immunotherapy”, 10-12, Journal for Immunotherapy of Cancer, 15,16, Biomed Central Ltd, London, UK, vol. 6, No. 1, Jun. 18, 2018 (Jun. 18, 2018), pp. 1-9, XP021…
[cited by applicant]
Young Arabella et al: “Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis”, Cancer research, vol. 77, No. 17, Sep. 1, 2017 (Sep. 1, 2017), pp. 4684-4696, XP055798544, 2019 San Antonio Breast…
[cited by applicant]
Allard et al., Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters 2018, 205, pp. 31-39.
[cited by applicant]
Azambuja et al., CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth, Molecular Neurobiology 2018, vol. 56, pp. 3260-3279, XP036763020.
[cited by applicant]
Cushman et al., Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance), Clin Cancer Res. 2015; 21(5): 1078-1086.
[cited by applicant]
DiRenzo et al., Methods for Assessment of the “Adenosine Fingerprint” in Clinical Trials of AB928, AACR 2019 National Meeting, Abstract # 3168, Poster Presentation.
[cited by applicant]
DiRenzo et al., P35 Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928, Journal for ImmunoTherapy of Cancer 2018, vol…
[cited by applicant]
Gao et al., CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity, BMC Cancer 2017, 17:135, pp. 1-8, XP093203406.
[cited by applicant]
Häusler et al., Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity, Cancer Immun…
[cited by applicant]
Linden et al., Purine Release, Metabolism, and Signaling in the Inflammatory Response, Annual Review of Immunology 2019, 37:325-347.
[cited by applicant]
Liu et al., Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor, Oncotarget 2013, vol. 4, No. 12, pp. 2366-2382.
[cited by applicant]
Lupia et al., CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports 2018, vol. 10, pp. 1412-1425, (include Supplementary information).
[cited by applicant]
OVCAR-3, Cellosaurus, [date of retrieval: Apr. 5, 2024], cellosaurus.org/CVCL_0465.txt, 8 pages.
[cited by applicant]
Rao et al., Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer, British Journal of Cancer 2017, 116(2):227-236.
[cited by applicant]
Scholz et al., 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018), Journal for ImmunoTherapy of Cancer 2018, pp. 1-398.
[cited by applicant]
SK-OV-3, Cellosaurus, [date of retrieval: Apr. 5, 2024], cellosaurus.org/CVCL_0532.txt, 8 pages.
[cited by applicant]
Tsuji et al., Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis, British Journal of Cancer 2012, 106, 126-132.
[cited by applicant]
Turcotte et al., CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer, Cancer Research 2015, 75(21): 4494-4503.
[cited by applicant]
Wu et al., High Expression of CD73 as a Poor Prognostic Biomarker in Human Colorectal Cancer, Journal of Surgical Oncology 2012;106:130-137.
[cited by applicant]
Yu et al., Extracellular 5′-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway, International Journal of Cancer 2017, vol. 142, pp. 959-967, XP093203410.
[cited by applicant]
Zhou et al., The distinct role of CD73 in the progression of pancreatic cancer, Journal of Molecular Medicine 2019, 97:803-815.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/025242 dated Sep. 28, 2021. 9 pages.
[cited by applicant]
Stagg et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene, Jul. 26, 2010, 29(39):5346-5358.
[cited by applicant]
Wainberg et al., “Nalirifox versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (Napoli 3): a randomised, open-label, phase 3 trial,” The Lancet, 2023, vol.…
[cited by applicant]
Wainberg et al., “ARC 8: Phase 1 / 1b Randomized Study of Quemliclustat + Gemcitabine / Nab paclitaxel ± Zimberelimab in Patients with Treatment Naive Metastatic Pancreatic Adenocarcinoma,” ASCO Gastrointestinal Cancers…
[cited by applicant]
Conroy et al., “Folfirinox versus Gemcitabine for Metastatic Pancreatic Cancer,” The New England Journal of Medicine, 2011, vol. 364, No. 19, pp. 1817-1825.
[cited by applicant]
Hay et al., “Targeting CD73 in the tumor microenvironment with MEDI9447”, Oncoimmunology 2016, vol. 5, No. 8 p. 1-10.
[cited by applicant]
Prior et al. “A Comprehensive Survey of Ras Mutations in Cancer”, Cancer Res. 2012, vol. 72, Iss. 10, p. 2457-2467.
[cited by applicant]
Nevedomekaya et al. “A Systems Oncology Approach Identifies NT5E as a Key metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity”, J. Proteome Res. 2016, vol. 15, Iss. 1, p. 280-290.
[cited by applicant]
Salazar et al. “CD73 Immunohistochemical Expression in Malignant Cells and correlation with Immune Infiltrate in Non-small Cell Lung Carcinoma (Nsclc)”, J. Thorac. Oncol. 2018, vol. 13, No. 10, Suppl. p. S533-S534.
[cited by applicant]